Does addition of intravitreal bevacizumab confer additional benefit in management of proliferative diabetic retinopathy?

Natasha Radhakrishnan, GopalS Pillai, Pooja Kandula, Mira Nair
{"title":"Does addition of intravitreal bevacizumab confer additional benefit in management of proliferative diabetic retinopathy?","authors":"Natasha Radhakrishnan, GopalS Pillai, Pooja Kandula, Mira Nair","doi":"10.18231/j.ijooo.2024.005","DOIUrl":null,"url":null,"abstract":"To evaluate visual outcome and complications of PDR after treatment with Intravitreal Bevacizumab followed by Pan Retinal Photocoagulation A hospital based retrospective study was done in the Department of Ophthalmology, to evaluate visual outcome and complications of PDR after treatment with intravitreal Bevacizumab followed by Pan Retinal Photocoagulation. Visual Acuity, Dilated fundus examination, OCT macula were done on subsequent follow ups 135 eyes of 133 patients were included in the study.The mean pre procedure visual acuity is 0.639±0.5327 which improved to 0.451±0.4089 post procedure. P value is <0.001 which is statistically significant.i.e, 94 (69.62%) eyes had improved vision, 21(15.55%) had stable vision and 20(14.81%) eyes had decreased vision. After injection followed by PRP out of 135 eyes,4(2.96%) eyes developed vitreous hemorrhage which resolved with repeat intravitreal anti-VEGF injection, 6(4.44%) eyes developed diabetic macular edema,3(2.2%) eyes developed Neovascularisation of iris and 4(2.96%)eyes developed vitreous hemorrhage with traction retinal detachment.From our study it appears that addition of intravitreal anti VEGF to Pan Retinal Photocoagulation for PDR confers the additional benefit of less incidence of vitreous hemorrhage and less incidence of traction retinal detachment requiring surgery in the 1 one year of follow up. This amounts to more compliance by the patient for taking the treatment as well as better visual outcome","PeriodicalId":14485,"journal":{"name":"IP International Journal of Ocular Oncology and Oculoplasty","volume":"15 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IP International Journal of Ocular Oncology and Oculoplasty","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijooo.2024.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

To evaluate visual outcome and complications of PDR after treatment with Intravitreal Bevacizumab followed by Pan Retinal Photocoagulation A hospital based retrospective study was done in the Department of Ophthalmology, to evaluate visual outcome and complications of PDR after treatment with intravitreal Bevacizumab followed by Pan Retinal Photocoagulation. Visual Acuity, Dilated fundus examination, OCT macula were done on subsequent follow ups 135 eyes of 133 patients were included in the study.The mean pre procedure visual acuity is 0.639±0.5327 which improved to 0.451±0.4089 post procedure. P value is <0.001 which is statistically significant.i.e, 94 (69.62%) eyes had improved vision, 21(15.55%) had stable vision and 20(14.81%) eyes had decreased vision. After injection followed by PRP out of 135 eyes,4(2.96%) eyes developed vitreous hemorrhage which resolved with repeat intravitreal anti-VEGF injection, 6(4.44%) eyes developed diabetic macular edema,3(2.2%) eyes developed Neovascularisation of iris and 4(2.96%)eyes developed vitreous hemorrhage with traction retinal detachment.From our study it appears that addition of intravitreal anti VEGF to Pan Retinal Photocoagulation for PDR confers the additional benefit of less incidence of vitreous hemorrhage and less incidence of traction retinal detachment requiring surgery in the 1 one year of follow up. This amounts to more compliance by the patient for taking the treatment as well as better visual outcome
在增殖性糖尿病视网膜病变的治疗中加入玻璃体内贝伐单抗是否会带来额外的益处?
评估玻璃体内贝伐单抗治疗后泛视网膜光凝的视觉疗效和并发症 眼科进行了一项基于医院的回顾性研究,评估玻璃体内贝伐单抗治疗后泛视网膜光凝的视觉疗效和并发症。研究纳入了 133 名患者的 135 只眼睛,在随后的随访中进行了视力、散瞳眼底检查和 OCT 黄斑检查。术前平均视力为 0.639±0.5327,术后视力提高到 0.451±0.4089。P值小于0.001,具有统计学意义,即94只眼睛(69.62%)视力提高,21只眼睛(15.55%)视力稳定,20只眼睛(14.81%)视力下降。在注射 PRP 后,135 只眼睛中有 4(2.96%)只眼睛出现玻璃体出血,再次进行玻璃体内抗血管内皮生长因子注射后,出血症状消失;6(4.44%)只眼睛出现糖尿病性黄斑水肿;3(2.2%)只眼睛出现虹膜血管新生;4(2.96%)只眼睛出现玻璃体出血并伴有牵引性视网膜脱离。从我们的研究中可以看出,在泛视网膜光凝治疗 PDR 的基础上加用玻璃体内抗血管内皮生长因子可带来额外的益处,即在一年的随访期间,玻璃体出血的发生率和需要手术的牵引性视网膜脱离的发生率较低。这就意味着患者更愿意接受治疗,视觉效果也会更好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信